Saturday, 11 Oct 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Green Cabbage Secures  Million Series B Funding to Accelerate Global Procurement Intelligence Expansion
    Green Cabbage Secures $40 Million Series B Funding to Accelerate Global Procurement Intelligence Expansion
    10/10/2025
    CHINA DRIVES STRONGEST GROWTH IN GLOBAL FACTORY PURCHASING SINCE MID-2022, WHILE NORTH AMERICAN MANUFACTURERS COOL IN SEPTEMBER: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
    CHINA DRIVES STRONGEST GROWTH IN GLOBAL FACTORY PURCHASING SINCE MID-2022, WHILE NORTH AMERICAN MANUFACTURERS COOL IN SEPTEMBER: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
    10/10/2025
    Fintech Forward 2025 Delivers with 38 Industry-Shaping Partnerships and Strategic Agreements Signed
    Fintech Forward 2025 Delivers with 38 Industry-Shaping Partnerships and Strategic Agreements Signed
    10/10/2025
    Kimberly-Clark Launches Enhanced Global Partnerships to Advance Essential Care for 24 Million Women and Girls
    Kimberly-Clark Launches Enhanced Global Partnerships to Advance Essential Care for 24 Million Women and Girls
    10/10/2025
    GEDU Group to Become Largest Foreign Education Investor in India
    GEDU Group to Become Largest Foreign Education Investor in India
    09/10/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • global
  • Business
  • june
  • announced
  • today
  •  and
  •  the
  • july
  • company
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

GlobeNews Wire
Last updated: 07/07/2025 10:22 AM
GlobeNews Wire
Share
2 Min Read
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SHARE
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Webcast Details
Apogee Therapeutics’ live webcast of the Phase 2 APEX Part A results will begin on Monday, July 7th at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company’s website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB
dan@1abmedia.com

Electric cars as batteries
IOC Presidentelect Kirsty Coventry shares her vision for the Olympic Movement with her leadership about to begin
BingX Joins ETHWarsaw as Sea Sponsor, Strengthening Web3 Community and Innovation
TV Rheinland Strengthens India Collaboration to Drive Global Quality and Skills Transformation
STARLight Project chosen as the European consortium to take the lead in next-generation Silicon Photonics on 300mm wafers
TAGGED: from the with16-week2025advancingapexapgapg777apogeeasthmaatopicbiologicsbiotechnologycallclinicalstagecompanyconferencecopddatadermatitisdifferentiateddosingefficacyeoefollowinghostincludingindicationsjulylargestmarketsmoderate-to-severemondayNasdaq:APGEnewsnovelpartpatientsphasepotentialreporttherapeuticstreatmenttrialUS03770N1019webcastwill
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

DXC Opens New Office in Buenos Aires, Reinforces Commitment to Growth in Latin America
Business

DXC Opens New Office in Buenos Aires, Reinforces Commitment to Growth in Latin America

09/08/2025
Four initiatives funded by the Olympic Refuge Foundation tackle inclusion and hate
Sports

Four initiatives funded by the Olympic Refuge Foundation tackle inclusion and hate

05/09/2025
Relativity Fest 2025: Relativity Announces Generative AI Solutions for Legal Review to Be Standard in Cloud Offering
Tech

Relativity Fest 2025: Relativity Announces Generative AI Solutions for Legal Review to Be Standard in Cloud Offering

09/10/2025
KuCoin Pay Partners with King Gift to Bridge Crypto to Everyday Shopping for Gaming, Entertainment, and Retail Gift Cards
Tech

KuCoin Pay Partners with King Gift to Bridge Crypto to Everyday Shopping for Gaming, Entertainment, and Retail Gift Cards

08/09/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?